Rachner et al. found that the TRAIL/OPG ratio was increased by zoledronic acid (ZA) in TRAIL-sensitive MDA-MB-231 cells, suggesting that the TRAIL/OPG cytokine system is among the bisphosphonate-responsive targets in breast cancer in vitro [60]. Here, TNFSF10 is linked to breast carcinoma.